Both in Biotechnology
AIM ImmunoTech vs Liminatus Pharma
Over the past year AIM returned −91.5% and LIMN returned −96.0%; their daily moves had a correlation of 0.05.
AIM −91.5% LIMN −96.0%Growth of $1, one year, split-adjusted
| Metric | AIM | LIMN |
|---|---|---|
| Price | $0.1521 | $2.63 |
| Market cap | $6.1M | $3.5M |
| Today | −5.53% | −5.88% |
| 1 month | −16.8% | −32.2% |
| 6 months | −72.8% | −73.8% |
| Year to date | −86.5% | −91.4% |
| 1 year | −90.5% | −95.9% |
| Revenue growth (YoY) | +4.0% | — |
| Gross margin | 80.8% | — |
| Net margin | −26876.9% | — |
| P/E (TTM) | — | — |
| Price / sales | 63.9× | — |
| Net cash | $6.3M | — |
| Dividend yield | — | — |
| Volatility (60d) | 68.6% | 1,152.6% |
| Short % of float | 3.6% | 4.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).